TY - JOUR A2 - Lewis, Valerae O. AU - Tenneti, Pavan AU - Zahid, Umar AU - Iftikhar, Ahmad AU - Yun, Seongseok AU - Sohail, Atif AU - Warraich, Zabih AU - Anwer, Faiz PY - 2018 DA - 2018/06/03 TI - Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Children and Young Adults with Relapsed Ewing’s Sarcoma: A Systematic Review SP - 2640674 VL - 2018 AB - Background。Relapsed Ewing’s sarcoma (RES) is an aggressive malignancy with poor survival. Although high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) given after conventional chemotherapy (CC) has shown survival benefits, it is not generally used in the United States for RES. We performed a systemic review to evaluate the benefits of HDCT for RES. Methods。Literature search involved Medline, Embase, and Cochrane database. We included studies with RES patients treated with HDCT/ASCT. Results。24研究总报告的345 RES patients that got HDCT were included in final analysis. Seventeen studies had patients with multiple malignancies including RES, while seven had only RES patients. At 2 and 3–5 years, event-free survival (EFS) in studies with only RES patients ranged 42–47% and 20–61% and overall survival (OS) ranged 50–66% and 33–77%, respectively. In studies with combined patients that reported outcomes of RES separately, the EFS at 1–3 and 4 years was 36–66% and 17–50%, respectively. The OS at 1-2 and 3-4 years was 40–60% and 50–70%. Conclusions。Most studies using HDCT/ASCT as consolidation regimen showed improved survival benefits compared to CC. Randomized controlled studies are needed to determine true clinical benefits of HDCT followed by ASCT in patients with RES. SN - 1357-714X UR - https://doi.org/10.1155/2018/2640674 DO - 10.1155/2018/2640674 JF - Sarcoma PB - Hindawi KW - ER -